Viela Biofounded In 2017 And Based In Gaithersburgmarylandis A Clinical Stage Biotechnology Company That Develops Treatments For Severe Autoimmune And Inflammatory Diseasesoriginally Acquired By Horizon Therapeutics In 2021It Became A Subsidiary Of Amgen Incin 2023The Company Specializes In Biologics That Target Shared Pathways In Autoimmune Conditionsutilizing Expertise In Monoclonal Antibodies And Cytokine Modulation Viela Bio S Product Pipeline Includes Inebilizumaba Humanized Monoclonal Antibody Approved For Neuromyelitis Optica Spectrum Disordernmosdand Currently In Phase Iii Trials For Myasthenia Gravis And Igg4 Related Diseasesother Candidates Include Vib4920A Cd40 Ligand Antagonist In Phase Ii Trialsand Vib7734An Anti Ilt7 Monoclonal Antibody In Early Stage Trialsthe Company Has Also Developed Preclinical Candidates Aimed At Suppressing Inflammationviela Bio Primarily Targets Patients With Rare Autoimmune Disorders And Has Established Collaborations For The Commercialization Of Its Products In Asia
No conferences found for this company.
| Company Name | Horizon Pharma Ireland Ltd |
| Country |
Ireland
|
| Address | 3100 Lake Drivecitywest Business Campusdublin 24 D24 Ak82 Ireland |
| Telephone | Login to View |
| Login to View |
